Levetiracetam guide history

Document Title

Clinical Guideline for Commencing Levetiracetam via Syringe Driver

Document Date

March 2021

Document Purpose and Intended Audience

This guideline has been produced to support the conversion or commencement of levetiracetam via continuous subcutaneous syringe driver in adult patients with a palliative diagnosis.

For use by palliative medicine specialists.


Dr Kate Holyhead

Dr Sharon Twigger

Consultation Process

Endorsed and approved by SPAGG


This guideline will be audited by members of the SPAGG group at least every 2 years. (CHECK - 4 years on this one - Monitoring not on the cover sheet)

Review Date

(must be within three years)

March 2025

Approval Signatures:

SPAGG chair

Dr Jon Tomas

SPAGG secretary

Dr Alice Gray

Date Approved by SPAGG: March 2018

Date submitted to Area Prescribing Committee: N/A

Version History

Version 1


March 2018

Summary of change/ process

Endorsed and approved by SPAGG

Version 2


March 2021

Summary of change/ process

Endorsed and approved by SPAGG

Disclaimer (SPAGG - Rewrite)

This Guide is intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.

Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.

While WMPCPS takes every care to compile accurate information , we cannot guarantee its correctness and completeness and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.